NYB (NYB Holdings) Inventories, Raw Materials & Components: $0.00 Mil (As of Sep. 2025)


What is NYB Holdings Inventories, Raw Materials & Components?

NYB Holdings NYB Inventories, Raw Materials & Components is $0.00 Mil as of Sep. 2025.

NYB Holdings's inventories, raw materials & components for the quarter that ended in Sep. 2025 was $0.00 Mil.

NYB Holdings Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for NYB Holdings's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings Inventories, Raw Materials & Components Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
Inventories, Raw Materials & Components
0.00 0.00

NYB Holdings Semi-Annual Data
Sep24 Sep25
Inventories, Raw Materials & Components 0.00 0.00

NYB Holdings Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $0.00 Mil mean?
NYB Holdings (NYB) has a Inventories, Raw Materials & Components of $0.00 Mil as of Sep. 2025. Raw materials are the components a company uses for its main products. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' Inventories, Raw Materials & Components too high?
NYB Holdings' current Inventories, Raw Materials & Components is $0.00 Mil.
How does NYB Holdings' Inventories, Raw Materials & Components compare to ?
NYB Holdings' Inventories, Raw Materials & Components of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on NYB Holdings and its competitors. NYB Holdings's current Inventories, Raw Materials & Components is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current Inventories, Raw Materials & Components of $0.00 Mil. The current Inventories, Raw Materials & Components is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For NYB Holdings (NYB), the current Inventories, Raw Materials & Components is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.